Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.71 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 13/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.54 |
| ▸ | HTR7 | P34969 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31612486 | 1.00 | SIGMAR1 (0.71) | SIGMAR1NR1H2CHRM3HTR1AHTR7 | |
| SCHEMBL32667553 | 0.88 | CHRM3 (0.67) | SIGMAR1NR1H2CHRM3 | |
| SCHEMBL1632938 | 0.87 | PRMT6 (0.61) | SIGMAR1CHRM3 | |
| SCHEMBL29823861 | 0.86 | CXCR4 (0.69) | SIGMAR1CHRM3 | |
| SCHEMBL3425973 | 0.84 | CYP2D6 (0.65) | SIGMAR1HTR1AFAAHDRD4DRD2 | |
| SCHEMBL3142583 | 0.84 | SIGMAR1 (0.79) | SIGMAR1 | |
| SCHEMBL1259602 | 0.84 | SIGMAR1 (0.71) | SIGMAR1 | |
| SCHEMBL21961925 | 0.84 | SIGMAR1 (0.71) | SIGMAR1 | |
| SCHEMBL152631 | 0.84 | SIGMAR1 (1.00) | SIGMAR1DRD4 | |
| SCHEMBL83548 | 0.84 | SIGMAR1 (1.00) | SIGMAR1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247600-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Lead Therapeutics, Inc. (US) | 2010-11-10 | — | — | EP | disclosed |
| US-20100105694-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ANDRES-GIL JOSE IGNACIO | 2010-04-29 | — | — | US | disclosed |
| US-20100105694-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ANDRES-GIL JOSE IGNACIO | 2010-04-29 | — | — | US | disclosed |
| US-20100105694-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ANDRES-GIL JOSE IGNACIO | 2010-04-29 | — | — | US | disclosed |
| EP-2091942-B1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-17 | — | — | EP | disclosed |
| EP-2091942-B1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-17 | — | — | EP | disclosed |
| EP-2091942-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009099736-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2008043775-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA NV (BE) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008043775-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA NV (BE) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105694-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, CHRNA5, ADRB2 | SIGMAR1 62/4885NR1H2 823/4885CHRM3 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.